Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its pioneering efforts to develop technology in the field of Spatial Surgery - a revolutionary new frontier ...
Over a 2- and 4-year follow-up *** Re-tear: 8.3% vs 25.8%; Relative risk=0.32 [95% Confidence Interval 0.13- 0.83]; p=0.0106. Smith+Nephew is a portfolio medical technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback